Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

The combination of lenalidomide and low-dose dexamethasone is an effective treatment for multiple myeloma (MM). Addition of alkylating agents to lenalidomide or thalidomide results in increased response rates and deeper responses. We designed this trial to study the combination of cyclophosphamide,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kumar, Shaji K., Lacy, Martha Q., Hayman, Suzanne R., Stewart, Keith, Buadi, Francis K., Allred, Jacob, Laumann, Kristina, Greipp, Philip R., Lust, John A., Gertz, Morie A., Zeldenrust, Steven R., Bergsagel, P. Leif, Reeder, Craig B., Witzig, Thomas E., Fonseca, Rafael, Russell, Stephen J., Mikhael, Joseph R., Dingli, David, Rajkumar, S. Vincent, Dispenzieri, Angela
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901994/
https://ncbi.nlm.nih.gov/pubmed/21630308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.22053
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items